Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data

[1]  R. Herbst,et al.  Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC , 2021, Nature Reviews Clinical Oncology.

[2]  K. Hiramatsu,et al.  Current Status, Challenges, and Future Perspectives of Real-World Data and Real-World Evidence in Japan , 2021, Drugs - Real World Outcomes.

[3]  H. Groen,et al.  Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands , 2021, Scientific Reports.

[4]  K. Kerr,et al.  The evolving landscape of biomarker testing for non-small cell lung cancer in Europe. , 2021, Lung cancer.

[5]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[6]  Ken Masamune,et al.  Effectiveness of drug postmarketing all-case surveillance as a safety measure in Japan , 2021, Therapeutic advances in drug safety.

[7]  Xiaoyun Li,et al.  Overall Survival With Second-Line Pembrolizumab in Patients With Non-Small-Cell Lung Cancer: Randomized Phase III Clinical Trial Versus Propensity-Adjusted Real-World Data. , 2021, JCO clinical cancer informatics.

[8]  J. Wolchok,et al.  The future of cancer immunotherapy: microenvironment-targeting combinations , 2020, Cell Research.

[9]  P. Conte,et al.  Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer. , 2020, Cancer treatment reviews.

[10]  V. Velcheti,et al.  Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practices. , 2019, Immunotherapy.

[11]  Gregory Riely,et al.  Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review. , 2019, JAMA.

[12]  J. Uchida,et al.  Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001) , 2019, Investigational New Drugs.

[13]  A. T. Freeman,et al.  Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice. , 2019, Lung cancer.

[14]  R. Herbst,et al.  Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes , 2019, Clinical Cancer Research.

[15]  Y. Shentu,et al.  Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  A. Tafreshi,et al.  Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[18]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[19]  Robert Sitton.  On Europe , 1992, Current History.